These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 36729084)

  • 21. IMPLICATION OF RECURRENT OR RETAINED FLUID ON OPTICAL COHERENCE TOMOGRAPHY FOR VISUAL ACUITY DURING ACTIVE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH A TREAT AND EXTEND PROTOCOL.
    Wickremasinghe SS; Janakan V; Sandhu SS; Amirul-Islam FM; Abedi F; Guymer RH
    Retina; 2016 Jul; 36(7):1331-9. PubMed ID: 26655608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spatial Correspondence Between Intraretinal Fluid, Subretinal Fluid, and Pigment Epithelial Detachment in Neovascular Age-Related Macular Degeneration.
    Klimscha S; Waldstein SM; Schlegl T; Bogunovic H; Sadeghipour A; Philip AM; Podkowinski D; Pablik E; Zhang L; Abramoff MD; Sonka M; Gerendas BS; Schmidt-Erfurth U
    Invest Ophthalmol Vis Sci; 2017 Aug; 58(10):4039-4048. PubMed ID: 28813577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
    Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
    Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome.
    Jang L; Gianniou C; Ambresin A; Mantel I
    Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1211-6. PubMed ID: 25267418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
    Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG;
    Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
    Steinle NC; Du W; Gibson A; Saroj N
    Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EFFECT OF RANIBIZUMAB AND AFLIBERCEPT ON RETINAL PIGMENT EPITHELIAL DETACHEMENT, SUBRETINAL AND INTRARETINAL FLUID IN AGE-RELATED MACULAR DEGENERATION.
    Sumarová P; Ovesná P; Matušková V; Beránek J; Michalec M; Michalcová L; Autrata D; Vysloužilová D; Chrapek O
    Cesk Slov Oftalmol; 2022; 78(4):176-185. PubMed ID: 35922146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.
    Jaffe GJ; Kaiser PK; Thompson D; Gibson A; Saroj N; Vitti R; Berliner AJ; Heier JS
    Ophthalmology; 2016 Sep; 123(9):1856-64. PubMed ID: 27369111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TOPOGRAPHIC ANALYSIS OF PHOTORECEPTOR LOSS CORRELATED WITH DISEASE MORPHOLOGY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Riedl S; Cooney L; Grechenig C; Sadeghipour A; Pablik E; Seaman JW; Waldstein SM; Schmidt-Erfurth U
    Retina; 2020 Nov; 40(11):2148-2157. PubMed ID: 31842189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Association of Fluid Volatility With Subretinal Hyperreflective Material and Ellipsoid Zone Integrity in Neovascular AMD.
    Ehlers JP; Patel N; Kaiser PK; Heier JS; Brown DM; Meng X; Reese J; Lunasco L; Le TK; Hu M; Srivastava SK
    Invest Ophthalmol Vis Sci; 2022 Jun; 63(6):17. PubMed ID: 35713892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Difference in characteristics and lesion reactivation between type 3 macular neovascularization with and without subretinal fluid at baseline.
    Kim JH; Kim JW; Kim CG
    Graefes Arch Clin Exp Ophthalmol; 2023 Feb; 261(2):401-408. PubMed ID: 36112220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.
    Stoller GL; Kokame GT; Dreyer RF; Shapiro H; Tuomi LL
    JAMA Ophthalmol; 2016 May; 134(5):545-553. PubMed ID: 27010625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept.
    Chatziralli I; Nicholson L; Vrizidou E; Koutsiouki C; Menon D; Sergentanis TN; Citu MC; Hamilton R; Patel PJ; Hykin P; Sivaprasad S
    Ophthalmology; 2016 Aug; 123(8):1762-1770. PubMed ID: 27289179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
    Monés J; Biarnés M;
    Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study.
    Hatz K; Prünte C
    Acta Ophthalmol; 2017 Feb; 95(1):e67-e72. PubMed ID: 27009503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early Predictive Factors of Visual Loss at 1 Year in Neovascular Age-Related Macular Degeneration under Anti-Vascular Endothelial Growth Factor.
    Kodjikian L; Rezkallah A; Decullier E; Aulagner G; Huot L; Mathis T;
    Ophthalmol Retina; 2022 Feb; 6(2):109-115. PubMed ID: 33991711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
    Sarraf D; London NJ; Khurana RN; Dugel PU; Gune S; Hill L; Tuomi L
    Ophthalmology; 2016 Oct; 123(10):2213-24. PubMed ID: 27566855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
    Braimah IZ; Agarwal K; Mansour A; Chhablani J;
    Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
    Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.